Acuitive Technologies, Inc. — SEC Form D Filing

Acuitive Technologies, Inc. filed an SEC Form D on September 24, 2026, reporting $1.88M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
September 24, 2026
Amount reported
$1.88M
Industry
Medical Devices
Website
https://www.acuitivetech.com/

What the company does

Securities: Simple Agreements for Future Equity (SAFEs). Exemption: Rule 506(b). Incorporated: NEW JERSEY

Problem

Patients experience various orthopedic issues in areas like the knee, foot, ankle, shoulder, elbow, and wrist, often requiring intervention such as filling bony voids or improving the biological and mechanical properties of soft tissue-to-bone interfaces, like in rotator cuff injuries.

Solution

Acuitive Technologies develops and manufactures medical devices based on CITREGEN Citrate Polymer Technology, including synthetic bone graft substitutes (CITREGRAFT) for filling bony voids, scaffolds (CITREBRIDGE) for rotator cuff repair, and soft tissue fixation devices (CITRELOCK, CITREFIX) for various orthopedic applications.

Verdict

Investors backed Acuitive Technologies to capitalize on novel material science, specifically its proprietary citrate polymer technology, which presented as a differentiated solution for various orthopedic repair needs. This cleared because the underlying technology promised broad application across high-volume procedures, not because it targeted a narrow, underserved niche. Investors were implicitly betting on the company's ability to translate lab-proven material advantages into competitive, FDA-approved devices. The investment horizon was limited by the need for extensive clinical validation and market adoption cycles typical of medical device commercialization.

Source: SEC EDGAR Form D filing